{"name":"Ascendis Pharma","slug":"ascendis","ticker":"ASND","exchange":"NASDAQ","domain":"ascendispharma.com","description":"Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.","hq":"Copenhagen, Denmark","founded":2007,"employees":"1189","ceo":"Jan Mikkelsen","sector":"Rare Endocrinology","stockPrice":241.79,"stockChange":-1.79,"stockChangePercent":-0.73,"marketCap":"$17.5B","metrics":{"revenue":1011424075.5754945,"revenueGrowth":144.3,"grossMargin":89,"rdSpend":0,"netIncome":579358654.6690944,"cash":669182206.1428225,"dividendYield":0,"peRatio":27.1,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Skytrofa","genericName":"LONAPEGSOMATROPIN","slug":"lonapegsomatropin","revenue":446000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2021-01-01","label":"Skytrofa first approved","drug":"Skytrofa","drugSlug":"lonapegsomatropin","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Yorvipath first approved","drug":"Yorvipath","drugSlug":"palopegteriparatide","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2029-03-01","label":"SKYTROFA Phase 3 readout (Turner Syndrome, Short Stature Homeobox Gene Mutation)","drug":"SKYTROFA","drugSlug":"lonapegsomatropin-tcgd","type":"phase3_readout","sentiment":"neutral"},{"date":"2034-06-01","label":"TransCon hGH patent cliff ($1.1B at risk)","drug":"TransCon hGH","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"TransCon PTH patent cliff ($500M at risk)","drug":"TransCon PTH","type":"patent_expiry","sentiment":"negative"},{"date":"2036-06-01","label":"TransCon CNP patent cliff ($200M at risk)","drug":"TransCon CNP","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":446000000,"percentOfTotal":100,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Skytrofa","genericName":"LONAPEGSOMATROPIN","slug":"lonapegsomatropin","indication":"Growth failure due to inadequate secretion of endogenous growth hormone (GH)","status":"marketed","revenue":446000000},{"name":"TransCon hGH","genericName":"TransCon hGH","slug":"transcon-hgh","indication":"Treatment of growth hormone deficiency in children and adults","status":"phase_3"},{"name":"SKYTROFA","genericName":"LONAPEGSOMATROPIN-TCGD","slug":"lonapegsomatropin-tcgd","indication":"Pediatric Growth Failure","status":"marketed"},{"name":"Yorvipath","genericName":"PALOPEGTERIPARATIDE","slug":"palopegteriparatide","indication":"hypoparathyroidism","status":"marketed"}]}],"pipeline":[{"name":"Skytrofa","genericName":"LONAPEGSOMATROPIN","slug":"lonapegsomatropin","phase":"marketed","mechanism":"Skytrofa works by mimicking the natural growth hormone to stimulate growth in individuals with growth hormone deficiency.","indications":["Growth failure due to inadequate secretion of endogenous growth hormone (GH)"],"catalyst":""},{"name":"TransCon hGH","genericName":"TransCon hGH","slug":"transcon-hgh","phase":"phase_3","mechanism":"TransCon hGH is a long-acting human growth hormone (hGH) analog that uses a proprietary technology called TransCon to extend its half-life.","indications":["Treatment of growth hormone deficiency in children and adults"],"catalyst":""},{"name":"SKYTROFA","genericName":"LONAPEGSOMATROPIN-TCGD","slug":"lonapegsomatropin-tcgd","phase":"marketed","mechanism":"SKYTROFA binds to the GH receptor, triggering signal transduction and various pharmacodynamic effects, including growth stimulation in pediatric GHD.","indications":["Pediatric Growth Failure","Adult Growth Hormone Deficiency"],"catalyst":""},{"name":"Yorvipath","genericName":"PALOPEGTERIPARATIDE","slug":"palopegteriparatide","phase":"marketed","mechanism":"Palopegteriparatide releases PTH(1-34) to maintain calcium and phosphate homeostasis through PTH1R.","indications":["hypoparathyroidism","acute post-surgical hypoparathyroidism"],"catalyst":""}],"recentEvents":[{"date":"2023-02-28","type":"earnings","headline":"Ascendis Pharma Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Ascendis Pharma reported its fourth quarter and full year 2022 financial results, with a net loss of $123.3 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2022-12-14","type":"deal","headline":"Ascendis Pharma Announces $100 Million At-The-Market Offering","summary":"Ascendis Pharma announced a $100 million at-the-market offering to support its ongoing development of rare endocrine treatments.","drugName":"","sentiment":"neutral"},{"date":"2022-09-22","type":"regulatory","headline":"FDA Accepts Ascendis Pharma's BLA for TransCon hGH for Pediatric Growth Hormone Deficiency","summary":"The FDA accepted Ascendis Pharma's BLA for TransCon hGH for pediatric growth hormone deficiency, with a PDUFA date of March 2024.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPZjJaRHFpTEYzVGdSZHl1VWdFXzU0SWtTWFFNd3NzSXVQQ2U4Z2FYdEd0aFNSUWlCTFl5QTRKRlJ3bm1KUU90ejVUcnd3MlFMYzVmZkVBQVMwdkVDS3RkVUVOMmJmUTZQTFRYbnZrWHBfZkZGSm9BME5BQVZWX2x1VEoxQ3Q0R05UZWowVGxFMVlUWDFBU0UycGRnQ3lLZXJoeU1wQndHYjlJZw?oc=5","date":"2026-04-08","type":"pipeline","source":"Stock Titan","summary":"Ascendis will swap every Nasdaq ADS for 1 ordinary share on April 20 - Stock Titan","headline":"Ascendis will swap every Nasdaq ADS for 1 ordinary share on April 20","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxONzBxVlJnVDFxTkZOM1I3bHY1LWFsb211UDVmaTd4Y1FDd0E2LXcwZTYzYkZ4eDZuRkFIUmpPNzBqNVlyNkdPc3BRQktKbkF3MHlGM3V3YVFGWVRxa05JcXUzZjZfV0VnMGZWMHU3UXBCTU5UX3JTcm5aX3dVZ3RwVjI4WE1qLVFZeFhvMG5R?oc=5","date":"2026-04-08","type":"pipeline","source":"Yahoo Finance UK","summary":"Ascendis Pharma to List Ordinary Shares Directly on Nasdaq - Yahoo Finance UK","headline":"Ascendis Pharma to List Ordinary Shares Directly on Nasdaq","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOOXo2THYtNzl0S0tablV1d2h0M1NvMS1pa2dDWGNoakU0aG0xcFhZMDM2b1ZzdFF6Tkg2VXp3aXJDclFabjQ5QVlmNlI0Vko1c3BQblRqZDJ2RTU3OWg4WXdMeVVXOWJaOFdVNDBqTDFOdktwV0hxS1FUb192YzBXMFJKYU5WQWxBVmE5WEt5dUQ4MUNHRlpjdDBTdm1zSEdNUGdJNERHRTNManBEdmVEN3RzbHYzenlnckRrZQ?oc=5","date":"2026-04-08","type":"pipeline","source":"GuruFocus","summary":"ASND: Promising Results from Ascendis Pharma's TransCon Therapies in Achondroplasia - GuruFocus","headline":"ASND: Promising Results from Ascendis Pharma's TransCon Therapies in Achondroplasia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQWm1mZFVacUkwYTJ6RlpXMl9fOEN4N1NvR2hoSkVhVVpPdkVJMHNiSDRXeTFMcGNLZ0ItYUpXMnpUWmZxRUVWdWFWU0RPV1NEblduLVlsUTNCU3NBanJkRVppWUsyVmFYaDFoUE1YV05PNmpLYmFlS2hlc2EwdzVKM29KekdFNkF6MUk3cmc3M0JjeDJmbmJ1NFV5a1dhNTdqRnZnQXJBT2RfT2dXcEJPc3FoT0NsV3JuZzRHcDVxTFhNRmd0c0lRZ1FQS0k2Tk1Xc0E?oc=5","date":"2026-04-07","type":"trial","source":"MSN","summary":"Ascendis Pharma A/S (ASND) reports positive week 52 data from phase 2 new InsiGHTS trial - MSN","headline":"Ascendis Pharma A/S (ASND) reports positive week 52 data from phase 2 new InsiGHTS trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxQNGh4dVo1NjlpbklYNV9fTUk5clFWcWxoZ1pEamVPX1FSZmJUdTdLQ2k2enZOMHNyb3dsRnBndzdnMkZ3a0ZFUWZJSk5UYVJmWENMZUpjNUZfNWRyT1hnUkFwRUd1ckJmalhOM2ZlVV93S1FpWXg0dmNDQm9DVE42RXE0bjV5aTZhcWlhdTJCNXI1N3dMWkExSWwycFhvNDZOSDFia1RvejJCZWZnTWN2dHdCbjJiSnU0dGhtZGlOMThQWHVnMUhPajB3X0lGMW1taDZXRGZfcFNDLXc?oc=5","date":"2026-04-07","type":"pipeline","source":"TipRanks","summary":"Ascendis Pharma Secures U.S. Orphan Drug Exclusivity and Launches YUVIWEL for Achondroplasia - TipRanks","headline":"Ascendis Pharma Secures U.S. Orphan Drug Exclusivity and Launches YUVIWEL for Achondroplasia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNUHdzZnEwWW02RWdBTFNyeDRMMkotT0RzN1RFM3BsN2RCOTFJTFI3UkFseU1Hbmp5QzJKWWRUZjJaZ2daRk44MUZGSkRnZk1vX19CNWh0SjFIbW9ZOFd2MHRyanRYMzJIOHVLVHVOY0U2VVBNeGxYMG15enhpelI2VmV2Z1BlMU1DcWNLTi1MZms5YnJCVjR6VjMtcENWanE1Skhpdm9CVTBuTTZHMC1hbzg1dml2QQ?oc=5","date":"2026-04-07","type":"regulatory","source":"Stock Titan","summary":"YUVIWEL earns FDA orphan exclusivity as Ascendis (ASND) starts U.S. launch - Stock Titan","headline":"YUVIWEL earns FDA orphan exclusivity as Ascendis (ASND) starts U.S. launch","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-06","type":"regulatory","source":"simplywall.st","summary":"A Look At Ascendis Pharma (ASND) Valuation After Key TransCon Trial Successes And Yuviwel FDA Approval - simplywall.st","headline":"A Look At Ascendis Pharma (ASND) Valuation After Key TransCon Trial Successes And Yuviwel FDA Approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxQZk5PQXMyS1NBMEt2dGZScHd2bU1kZGN0R28ySWFTWk9kNXlpS3czMWM3ZGhjS1lKOEl0RnEyM3NtTUJUa0F5eFJ6b0ZsT1M5N08xZjBaWDg5d3VxZC1ldWxVZy1ldmJIdFR1eW5aX2hITUh2aGtSOFZ6VWRfNEtOOXBjeFBac2F4bmlFQjJrWnowNUlUYmVidnAzYTFzdGc4dVB2VEttc3F3ci00c3RzV0NuTHRjanh4TjBSSTNXdlJlNkVfdlpsaElxR3BOWXBuc2I0dGg2YlhSUVVFQVNZWnptakZoU3liblNRMkEzTkY0LXdGTzRVdGt0VF9SZw?oc=5","date":"2026-04-06","type":"pipeline","source":"globenewswire.com","summary":"Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States - globenewswire.com","headline":"Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQYUE0OTVjd1JRaTlocWtPMEpOQmIyVHkyTmt0QU5TSnZ1X243N3BHVUNVNnJGOHRwMzRidmctb2xaTmFhc0p2QUtLb29yYXdydDVVTllETDFIYWpUbFhseTRWdXNncE1WeFdudktMVE92ME9vcFRfVy05LVZJUE9vYnFLYjd5RkxQalV5OVM0azJRMEJxTjBXaXllNkJGRHJNaFdzUmRKdnVjUQ?oc=5","date":"2026-04-06","type":"trial","source":"Yahoo Finance","summary":"How Turner and Achondroplasia Data plus Board Addition Could Shape Ascendis Pharma’s (ASND) Pipeline Strategy - Yahoo Finance","headline":"How Turner and Achondroplasia Data plus Board Addition Could Shape Ascendis Pharma’s (ASND) Pipeline Strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOdGktNVNycDZxal9QV3FLWFNmbjV0T1B0bFJsOVJkR0kzellkSGlXNm1tZWRZRGttR3c0WUJ2TmlkUEhxemctUnoyOW5XXzB2NTFtUWM0WmRsWHpnblVXQnFyeUdwZ1VyY1FKMlhaWVJKZko0WjhRa0lFSzdNcWdJTDhEYVZzNkhPckdSYUxxS1dxTnU1QWR6eU5VSV9PR0d1cmtXSDNvZXg?oc=5","date":"2026-04-06","type":"regulatory","source":"GuruFocus","summary":"Ascendis Pharma (ASND) Gains FDA Orphan Drug Exclusivity for Yuviwel - GuruFocus","headline":"Ascendis Pharma (ASND) Gains FDA Orphan Drug Exclusivity for Yuviwel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNeTZ1VThiZUY0djk4eUFNWnI3VUN2WHdRRlBkelVFaHZ3aVFQbHFBNTFOVTJoN1p4OTFSQi1reWtXQ19hdGlQZjJBWkhTR0dScVpiMFdLLTBVOXlBZFUxclJkZ0VpUXhYVHRPQk5DRVVBNndrRThRbU12RTJISlBsc2lQelVMSFUwTnBuNVY1YTBYMTUwTjhIWmpkN3Y5UUlNRkQxZkZodnlYZVpFS25zcndXY21ZRE1HWFBCSlFOT3IwMS1SbFQzTno2VnVldklBRXNqYmIxTXFNUWE4ZEljVw?oc=5","date":"2026-04-04","type":"deal","source":"MarketBeat","summary":"Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of \"Moderate Buy\" from Analysts - MarketBeat","headline":"Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of \"Moderate Buy\" from Analysts","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-01","type":"pipeline","source":"simplywall.st","summary":"Is It Time To Reassess Ascendis Pharma (ASND) After Its Strong Multi‑Year Share Price Run? - simplywall.st","headline":"Is It Time To Reassess Ascendis Pharma (ASND) After Its Strong Multi‑Year Share Price Run?","sentiment":"neutral"}],"patents":[{"drugName":"TransCon hGH","drugSlug":"somatropin","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1100000000},{"drugName":"TransCon PTH","drugSlug":"parathyroid-hormone","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":500000000},{"drugName":"TransCon CNP","drugSlug":"cerebellar-neurotrophic-factor","patentNumber":"","type":"Patent Cliff","expiryDate":"2036-06-01","territory":"US","annualRevenue":200000000}],"drugCount":4,"phaseCounts":{"marketed":3,"phase_3":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Sarepta Therapeutics","BioMarin Pharmaceutical","Pfizer"],"therapeuticFocus":["Rare Endocrinology"],"financials":{"source":"yahoo_finance","revenue":841275701.6076001,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":841275701.6076001},{"period":"2024-12-31","value":424814252.67630005},{"period":"2023-12-31","value":311586448.8474},{"period":"2022-12-31","value":59782710.328200005}],"grossProfit":730393692.1731001,"grossProfitHistory":[{"period":"2025-12-31","value":730393692.1731001},{"period":"2024-12-31","value":373110981.60690004},{"period":"2023-12-31","value":259723131.04890004},{"period":"2022-12-31","value":45603971.99910001}],"rdSpend":354697430.19030005,"rdSpendHistory":[{"period":"2025-12-31","value":354697430.19030005},{"period":"2024-12-31","value":358649532.9972},{"period":"2023-12-31","value":483007009.7322},{"period":"2022-12-31","value":443485981.6632}],"sgaSpend":523415888.2692,"operatingIncome":-159195093.58530003,"operatingIncomeHistory":[{"period":"2025-12-31","value":-159195093.58530003},{"period":"2024-12-31","value":-325657710.54090005},{"period":"2023-12-31","value":-532174065.84630007},{"period":"2022-12-31","value":-656324766.8802}],"netIncome":-266394860.02620003,"netIncomeHistory":[{"period":"2025-12-31","value":-266394860.02620003},{"period":"2024-12-31","value":-441686916.24120003},{"period":"2023-12-31","value":-562438084.5621},{"period":"2022-12-31","value":-681301402.4142001}],"eps":-3.76,"epsHistory":[{"period":"2025-12-31","value":-3.76},{"period":"2024-12-31","value":-6.53},{"period":"2023-12-31","value":-8.55},{"period":"2022-12-31","value":-10.4}],"cash":719674065.9963001,"cashHistory":[{"period":"2025-12-31","value":719674065.9963001},{"period":"2024-12-31","value":653671729.4949001},{"period":"2023-12-31","value":458135514.3852},{"period":"2022-12-31","value":519587617.23810005}],"totalAssets":1521693926.4510002,"totalLiabilities":1711905375.2013001,"totalDebt":1018441589.5998001,"equity":-190211448.75030002,"operatingCashflow":62963785.097100005,"operatingCashflowHistory":[{"period":"2025-12-31","value":62963785.097100005},{"period":"2024-12-31","value":-357706775.9871},{"period":"2023-12-31","value":-545982477.0723001},{"period":"2022-12-31","value":-579087617.2857001}],"capex":-9912383.185500002,"capexHistory":[{"period":"2025-12-31","value":-9912383.185500002},{"period":"2024-12-31","value":-1667056.0761000002},{"period":"2023-12-31","value":-2852803.7406},{"period":"2022-12-31","value":-16926401.8827}],"freeCashflow":53051401.9116,"dividendsPaid":null,"buybacks":-20322429.9228,"employees":1189,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":169661215.08900002,"ebit":22287383.195400003,"ebitda":27217289.741400003,"period":"2026-03-31","revenue":288085280.6043,"epsBasic":10.2,"netIncome":735209112.7377001,"rdExpense":68976635.56920001,"epsDiluted":9.75,"grossProfit":267623831.98980004,"operatingIncome":28985981.331600003},{"sga":157707944.0514,"ebit":-7204439.2581,"ebitda":-1568925.2349,"period":"2025-12-31","revenue":289135514.25,"epsBasic":-0.55,"netIncome":-39207943.9566,"rdExpense":91297897.26930001,"epsDiluted":-0.55,"grossProfit":261567757.21860003,"operatingIncome":7525700.9406},{"sga":130475467.39410001,"ebit":-43984813.1193,"ebitda":-39289719.6576,"period":"2025-09-30","revenue":249572430.1062,"epsBasic":-1,"netIncome":-71248831.8327,"rdExpense":78129672.9597,"epsDiluted":-1,"grossProfit":223457944.10400003,"operatingIncome":12846962.627100002},{"sga":123492990.753,"ebit":-2323598.1327000004,"ebitda":2709112.1517000003,"period":"2025-06-30","revenue":184632009.49350002,"epsBasic":-0.64,"netIncome":-45391355.17650001,"rdExpense":84098130.90840001,"epsDiluted":-0.82,"grossProfit":147894859.9314,"operatingIncome":-61858644.90930001},{"sga":118044392.61780001,"ebit":-56984813.129700005,"ebitda":-51675233.68620001,"period":"2025-03-31","revenue":117936915.98220001,"epsBasic":-1.58,"netIncome":-110544392.61180001,"rdExpense":101171729.05290002,"epsDiluted":-1.58,"grossProfit":97473130.9191,"operatingIncome":-121742990.75160001},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":241.79,"previousClose":243.58,"fiftyTwoWeekHigh":250.74,"fiftyTwoWeekLow":150.89,"fiftyTwoWeekRange":"150.89 - 250.74","fiftyDayAverage":231.7,"twoHundredDayAverage":212.97,"beta":0,"enterpriseValue":18052554182.666344,"forwardPE":21.8,"priceToBook":26.16,"priceToSales":17.25,"enterpriseToRevenue":17.85,"enterpriseToEbitda":-1511.44,"pegRatio":0,"ebitda":-11943925.2432,"ebitdaMargin":-1.2,"freeCashflow":138119308.52171043,"operatingCashflow":70664719.68270001,"totalDebt":1047504673.7352,"debtToEquity":183.8,"currentRatio":1,"returnOnAssets":-0.6,"returnOnEquity":332.7,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":7,"targetMeanPrice":296.37,"targetHighPrice":342.46,"targetLowPrice":254.12,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.8,"institutionHeldPercent":106.6,"sharesOutstanding":61779750,"floatShares":62111595,"sharesShort":2832689,"shortRatio":2.71,"shortPercentOfFloat":4.6,"epsTrailing":8.92,"epsForward":11.1,"revenuePerShare":14.19,"bookValue":9.24,"officers":[{"age":65,"name":"Mr. Jan Moller Mikkelsen","title":"President, CEO, Member of Executive Board & Executive Director"},{"age":51,"name":"Mr. Scott T. Smith","title":"CFO, Executive VP & Member of Executive Board"},{"age":64,"name":"Ms. Pedersen Anni Lotte Kirstine Sonderbjerg","title":"Executive VP, Chief Administrative Officer & Member of the Executive Board"},{"age":54,"name":"Mr. Michael Wolff Jensen L.L.M.","title":"Executive VP, Chief Legal Officer & Member of the Executive Board"},{"age":55,"name":"Mr. Mads  Bodenhoff","title":"Senior VP, Head of Finance & Principal Accounting Officer"},{"age":null,"name":"Mr. Chad  Fugure","title":"Vice President of Investor Relations"},{"age":64,"name":"Mr. Flemming Steen Jensen","title":"Executive Vice President of Product Supply & Quality"},{"age":46,"name":"Dr. Kennett  Sprogoe Ph.D.","title":"Executive VP and Head of Research & Product Development"}],"industry":"Biotechnology","irWebsite":"","website":"https://ascendispharma.com","phone":"45 70 22 22 44"}}